Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

MIRV

Antibody-drug conjugate · developed by AbbVie

Phase 3 Most advanced trial
1 Registered trials

What is MIRV?

MIRV is named in the trial record as a treatment studied in ovarian neoplasms, fallopian tube neoplasms, and peritoneal neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Therapy area
Oncology
Developer
AbbVie
In trials of
LLY
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07213804 Phase 3 Ovarian Neoplasms Recruiting LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fallopian Tube NeoplasmsNeoplasm MetastasisOvarian NeoplasmsPeritoneal Neoplasms

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.